Krystal Biotech Stock
Krystal Biotech Stock
Krystal Biotech gained 2.910% today.
The stock is an absolute favorite of our community with 25 Buy predictions and no Sell predictions.
On the other hand, the target price of 215 € is below the current price of 233.3 € for Krystal Biotech, so the potential is actually -7.84%.
So far the community has only identified positive things for Krystal Biotech stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Krystal Biotech in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | 2.910% | -6.708% | -4.828% | 26.861% | 4.566% | 204.295% | - |
| Biocryst Pharmaceuticals | 1.020% | 10.239% | 12.387% | -18.207% | -1.464% | -25.162% | -33.512% |
| Heron Therapeutics Inc. | 6.950% | -7.850% | -25.626% | -45.666% | -17.280% | -57.269% | -93.736% |
| Madrigal Pharmaceuticals inc. | -1.100% | -9.044% | -8.016% | 21.382% | -24.955% | 42.786% | 270.213% |
Comments
Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $220.00 to $323.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for KRYS provided by MarketBeat